Amgen Inc. (NASDAQ:AMGN) Shares Set to Pay Quarterly Dividend of $2.52

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Tuesday, October 27th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share by the medical research company on Friday, December 11th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, November 20th.

Amgen has increased its dividend by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $24.61 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 41.0%.

Amgen Trading Up 0.7%

Amgen stock opened at $447.95 on Wednesday. Amgen has a twelve month low of $288.00 and a twelve month high of $450.98. The firm’s 50 day moving average price is $418.42 and its two-hundred day moving average price is $372.80.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the business earned $6.02 EPS. The company’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts expect that Amgen will post 22.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

AMGN has been the topic of a number of recent research reports. HSBC downgraded Amgen from a “buy” rating to a “hold” rating and lowered their target price for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. Truist Financial lifted their price target on Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday, October 7th. Guggenheim lowered their price target on Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a research note on Tuesday, October 13th. Scotiabank increased their price objective on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Finally, UBS Group lifted their target price on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research note on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $389.71.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.